UBS Group’s Athira Pharma ATHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $61.4K | Buy |
203,475
+126,924
| +166% | +$38.3K | ﹤0.01% | 6325 |
|
|
2025
Q1 | $21.8K | Sell |
76,551
-10,425
| -12% | -$2.97K | ﹤0.01% | 6875 |
|
|
2024
Q4 | $51.1K | Buy |
86,976
+75,148
| +635% | +$44.1K | ﹤0.01% | 6058 |
|
|
2024
Q3 | $5.28K | Buy |
11,828
+10,896
| +1,169% | +$4.86K | ﹤0.01% | 6862 |
|
|
2024
Q2 | $2.47K | Hold |
932
| – | – | ﹤0.01% | 7191 |
|
|
2024
Q1 | $2.55K | Hold |
932
| – | – | ﹤0.01% | 6703 |
|
|
2023
Q4 | $2.27K | Sell |
932
-98,570
| -99% | -$240K | ﹤0.01% | 6919 |
|
|
2023
Q3 | $201K | Buy |
99,502
+71,206
| +252% | +$144K | ﹤0.01% | 4277 |
|
|
2023
Q2 | $83.5K | Buy |
28,296
+4,809
| +20% | +$14.2K | ﹤0.01% | 5099 |
|
|
2023
Q1 | $58.7K | Sell |
23,487
-79,357
| -77% | -$198K | ﹤0.01% | 5246 |
|
|
2022
Q4 | $326K | Buy |
102,844
+37,722
| +58% | +$120K | ﹤0.01% | 4011 |
|
|
2022
Q3 | $193K | Buy |
65,122
+8,287
| +15% | +$24.6K | ﹤0.01% | 4085 |
|
|
2022
Q2 | $173K | Buy |
56,835
+520
| +0.9% | +$1.58K | ﹤0.01% | 4054 |
|
|
2022
Q1 | $760K | Buy |
56,315
+43,120
| +327% | +$582K | ﹤0.01% | 3461 |
|
|
2021
Q4 | $172K | Sell |
13,195
-55,499
| -81% | -$723K | ﹤0.01% | 4779 |
|
|
2021
Q3 | $644K | Buy |
68,694
+67,434
| +5,352% | +$632K | ﹤0.01% | 3557 |
|
|
2021
Q2 | $13K | Buy |
1,260
+560
| +80% | +$5.78K | ﹤0.01% | 6669 |
|
|
2021
Q1 | $13K | Sell |
700
-163,152
| -100% | -$3.03M | ﹤0.01% | 6701 |
|
|
2020
Q4 | $5.61M | Buy |
163,852
+138,883
| +556% | +$4.76M | ﹤0.01% | 1751 |
|
|
2020
Q3 | $461K | Buy |
+24,969
| New | +$461K | ﹤0.01% | 3486 |
|